These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29237549)

  • 1. Modeling Parkinson's disease and treatment complications in rodents: Potentials and pitfalls of the current options.
    Francardo V
    Behav Brain Res; 2018 Oct; 352():142-150. PubMed ID: 29237549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Animal models of L-DOPA-induced dyskinesia: an update on the current options.
    Iderberg H; Francardo V; Pioli EY
    Neuroscience; 2012 Jun; 211():13-27. PubMed ID: 22465440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are rodent models of Parkinson's disease behaving as they should?
    Vingill S; Connor-Robson N; Wade-Martins R
    Behav Brain Res; 2018 Oct; 352():133-141. PubMed ID: 29074404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental Models of l-DOPA-Induced Dyskinesia.
    Johnston TH; Lane EL
    Int Rev Neurobiol; 2011; 98():55-93. PubMed ID: 21907083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP.
    Schober A
    Cell Tissue Res; 2004 Oct; 318(1):215-24. PubMed ID: 15503155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exercise as a therapeutic intervention for motor and non-motor symptoms in Parkinson's disease: Evidence from rodent models.
    Crowley EK; Nolan YM; Sullivan AM
    Prog Neurobiol; 2019 Jan; 172():2-22. PubMed ID: 30481560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
    Ando K; Inoue T; Itoh T
    Pharmacol Biochem Behav; 2014 Dec; 127():62-9. PubMed ID: 25449794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson's disease treated with L-DOPA.
    Zhao TT; Kim KS; Shin KS; Park HJ; Kim HJ; Lee KE; Lee MK
    BMC Complement Altern Med; 2017 Sep; 17(1):449. PubMed ID: 28877690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Ravenscroft P; McGuire S; Crossman AR; Menniti FS; Brotchie JM
    Exp Neurol; 2004 Aug; 188(2):471-9. PubMed ID: 15246846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice.
    Cenci MA; Lundblad M
    Curr Protoc Neurosci; 2007 Oct; Chapter 9():Unit 9.25. PubMed ID: 18428668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.
    Bézard E; Muñoz A; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
    Neurosci Res; 2013 Dec; 77(4):242-6. PubMed ID: 24135129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous cerebroventricular administration of dopamine: A new treatment for severe dyskinesia in Parkinson's disease?
    Laloux C; Gouel F; Lachaud C; Timmerman K; Do Van B; Jonneaux A; Petrault M; Garcon G; Rouaix N; Moreau C; Bordet R; Duce JA; Devedjian JC; Devos D
    Neurobiol Dis; 2017 Jul; 103():24-31. PubMed ID: 28363801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model.
    Park HY; Ryu YK; Kim YH; Park TS; Go J; Hwang JH; Choi DH; Rhee M; Lee CH; Kim KS
    Neurobiol Dis; 2016 May; 89():169-79. PubMed ID: 26875664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
    Lindenbach D; Conti MM; Ostock CY; George JA; Goldenberg AA; Melikhov-Sosin M; Nuss EE; Bishop C
    J Neurosci; 2016 Sep; 36(38):9873-87. PubMed ID: 27656025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rodent models of impulsive-compulsive behaviors in Parkinson's disease: How far have we reached?
    Cenci MA; Francardo V; O'Sullivan SS; Lindgren HS
    Neurobiol Dis; 2015 Oct; 82():561-573. PubMed ID: 26325219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
    Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
    Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral models of Parkinson's disease in rodents: a new look at an old problem.
    Meredith GE; Kang UJ
    Mov Disord; 2006 Oct; 21(10):1595-606. PubMed ID: 16830310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.